The health economics of bladder cancer

By M. Botteman, C. Pashos, A. Redaelli, B. Laskin, R. Hauser. PharmacoEconomics (Auckland), 2012

769 citations recorded by the source corpus.

Subfields: Surgery

View Paper: https://www.semanticscholar.org/paper/ad21f983add2fc0e8e96cebeee4822c734fda799

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Siefker-Radtke
2. J. Hoffman-Censits
3. Keith A. Baggerly
4. M. Tran
5. S. Pretzsch
6. Tadeusz Majewski
7. Seungchan Kim
8. W. Choi

Citations in the corpus

• Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy (2014, positive): “Low-grade non-muscle invasive (‘‘superficial’’) cancers, which account for 70% of tumor incidence, are not immediately life-threatening, but they have a propensity for recurrence that necessitates costly lifelong surveillance (Botteman et al., 2003).”